IL1A and cancer: Both the IL-1α receptor blocker anakinra and the IL-1β receptor blocker canakinumab have been the subject of clinical trials and intense interest in the cancer field following news that the CANTOS trial unexpectedly showed that use of canakinumab to block IL-1 signaling was associated with a lower incidence and mortality from lung cancer [9,10].